Abu Dhabi Investment Authority (ADIA) and HarbourVest are exploring the possibility of acquiring a minority stake in Cohance Lifesciences, a Hyderabad-based pharmaceutical platform owned by Advent International. The investment is expected to be around $350-400 million, valuing Cohance Lifesciences at approximately $1.5 billion. ADIA already has a presence in India’s pharmaceutical sector, owning a stake in Intas Pharmaceuticals.